Studies on Lipoprotein Metabolism in Hyperlipidemics on Simfibrate Treatment

Abstract

Effects of simfibrate on serum lipids and lipoprotein metabolism were studied in 40 patients with hyperlipidemia. The patients received 1, 500mg of simfibrate everyday for 8 or 12 weeks. Serum lipids and apoprotein A-I and C-III were measured in every four week during the treatment. By simfibrate treatment, cholesterol levels decreased by 10 to 20% of the initial values and triglyceride decreased 40 to 50% of the initial values. Simfibrate increased HDL cholesterol levels by 20% of the initial values. Apoprotein A-I increased by 20% and C-III decreased by 30% of the initial values. These results indicated that simfibrate reduced the levels of very low and low density lipoprotein and increased the levels of high density lipoprotein.